"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 3 | 6 |
| 1998 | 1 | 3 | 4 |
| 1999 | 0 | 2 | 2 |
| 2000 | 3 | 3 | 6 |
| 2001 | 1 | 3 | 4 |
| 2002 | 4 | 2 | 6 |
| 2003 | 3 | 2 | 5 |
| 2004 | 4 | 1 | 5 |
| 2005 | 5 | 4 | 9 |
| 2006 | 5 | 4 | 9 |
| 2007 | 3 | 4 | 7 |
| 2008 | 5 | 3 | 8 |
| 2009 | 4 | 6 | 10 |
| 2010 | 2 | 5 | 7 |
| 2011 | 6 | 5 | 11 |
| 2012 | 3 | 1 | 4 |
| 2013 | 7 | 7 | 14 |
| 2014 | 10 | 7 | 17 |
| 2015 | 11 | 7 | 18 |
| 2016 | 6 | 3 | 9 |
| 2017 | 10 | 4 | 14 |
| 2018 | 4 | 9 | 13 |
| 2019 | 9 | 10 | 19 |
| 2020 | 2 | 5 | 7 |
| 2021 | 1 | 10 | 11 |
| 2022 | 2 | 4 | 6 |
| 2023 | 0 | 4 | 4 |
| 2024 | 8 | 6 | 14 |
| 2025 | 11 | 4 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025 Nov; 229:112910.
-
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Endocr Pract. 2026 Jan; 32(1):23-30.
-
Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide. Ophthalmol Retina. 2026 Feb; 10(2):142-151.
-
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk. J Am Heart Assoc. 2025 Aug 05; 14(15):e040217.
-
Metabolic Models, in Silico Trials, and Algorithms. J Diabetes Sci Technol. 2025 Jul; 19(4):895-907.
-
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025 Jul; 19(4):937-949.
-
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. Diabetes Technol Ther. 2025 Jul; 27(S3):S60-S71.
-
Metabolic Models, in Silico Trials, and Algorithms. Diabetes Technol Ther. 2025 Jul; 27(S3):S21-S32.
-
Approach to the Patient Using Diabetes Technology in Pregnancy. J Clin Endocrinol Metab. 2025 Jun 17; 110(7):e2317-e2326.
-
Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively. J Am Acad Orthop Surg. 2025 Jun 17; 33(16):e971-e978.